Taysha Secures Commercial Manufacturing for Rett Gene Therapy Ahead of Potential Launch
TSHA has more than doubled off its 52-week low of $2.54.
Summary
Taysha has expanded its partnership with Catalent to include commercial manufacturing of TSHA-102, its lead gene therapy for Rett syndrome. This secures long-term capacity and a scalable supply framework for a potential launch following FDA approval. The move signals launch readiness and de-risks manufacturing, a critical step for a company with a $1.9B market cap and a pivotal trial recently fully dosed. It follows the June 2026 $200M offering that strengthened the balance sheet, and aligns with management's stated focus on commercial infrastructure. The agreement leverages Catalent's FDA-licensed gene therapy facility and experience across 90+ programs, adding credibility to Taysha's commercial ambitions.
At the time of this announcement, TSHA was trading at $5.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $2.54 to $7.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.